DISPATCHES FROM THE GUILD CONFERENCE, SERIES #35

Management of Large Colon Polyps

Read Article

Colorectal cancer is the third most common cancer in the United States. Pre-cancerous colon polyps are precursors to most colorectal cancers, and colonoscopy reduces the incidence of colorectal cancer by removal of these polyps. The risk of cancer is especially higher in polyps > 20 mm in size, NICE 3 or Kudos VI or VN features. Management of large colon polyps includes optimal detection and recognition especially for sessile polyps, assessment of polyp morphology and histology, endoscopist’s comfort in advanced polypectomy techniques as well as managing associated adverse events.

Introduction

Colorectal cancer (CRC) is the third most common cause of cancer-related deaths in the United States.1 Colon polyps with certain histology are the precursors to most CRCs.2 Colonoscopy with polypectomy reduces both the incidence as well as the mortality associated with CRC.3,4 Previous studies have shown that removal of adenomatous polyps during colonoscopy is associated with 50% reduction in CRC-related mortality. 3,4 Therefore, optimizing the management of colon polyps is essential. This is especially important in large polyps. When the size of polyps is larger than 20 mm, the risk of cancer in these polyps increases.5 In this review, we will discuss techniques of management of large colon polyps.

Inspection

The first step in managing large colon polyps is being able to recognize them. Flat or sessile polyps especially in the right colon can be often missed. Hence, studies have shown that a second look in the right colon whether in forward view or in retroflexion during colonoscopy can improve the detection rates of these polyps.6 Needless to add that high-quality colonoscopy is essential in recognizing polyps. This includes a good bowel preparation, adequate withdrawal time and an endoscopist with an adenoma detection rate meeting standard guidelines.7,8

Once a large polyp is identified, the next step is to carefully assess the polyp for size, location and morphology.9-11 This is important to determine whether endoscopic resection is safely possible and the optimal modality of endoscopic resection. While studies have shown that there is only moderate agreement among experts when it comes to classifying large polyps according to various classifications,12 there are several available classifications. In the US, the most commonly used are the Paris classification,13 narrow band imaging international colorectal endoscopic (NICE) classification,14 and Kudo’s classification of polyp pit pattern among others.15

Classification Systems to assess polyps

The Paris classification classifies polyps as pedunculated (1p), sessile (1s), flat (IIa, IIb, IIc) or ulcerated (III).13 For non-pedunculated polyps (Paris classification 1s and II), surface morphology should also be classified as granular or non-granular laterally spreading tumors. The NICE classification classifies lesions as type 1 (serrated class: either hyperplastic or sessile serrated polyp), type 2 (conventional adenomas) or type 3 (deep submucosal invasive cancer).14 Another classification system, especially popular in Eastern part of the world is the Kudo pit pattern classification system.15 It requires magnification during colonoscopy using chromoendoscopy and evaluation of the pit pattern of the polyps. Pits are openings for the crypts. The Kudo classification classifies pit pattern as round / normal (Type I), asteroid (Type II), tubular or round pit smaller than normal pit (Type IIIS), tubular or round pit larger than normal pit (Type IIIL), gyrus/dendritic (IV), irregular arrangement (VI), and loss of decrease of pits with amorphous structure (VN). Polyps with type I to IV pit pattern are endoscopically resectable, while those with type VI and VN are suggestive of invasion and neoplasia.

What makes a polyp unresectable?

While all the above classifications are helpful in standardizing the nomenclature of how we describe large polyps, it is important to note that reports have shown variability in agreement among experts regarding polyp classifications.12 Therefore, the most practical recommendation for endoscopists is to recognize which polyps are amenable to endoscopic resection. Histological features that are unfavorable (lymphovascular invasion, tumor budding, poor differentiation) are not always predictable before resection.16

Depth of submucosal invasion can be predicted based upon lesion morphology and pit pattern as described above. Non-granular surface particularly pseudodepressed subtype, redness, expansion, firmness and fold convergence can all be associated with submucosal invasive carcinoma.17 Areas in polyp which do not lift with submucosal injection are also worrisome for invasive cancer.18,19 Prior reports have shown that the positive predictive value for invasive cancer if non-lifting sign is present can be 80% in treatment-naïve lesions.19,20 Non-lifting sign can be seen in lesions which have been previously biopsied or endoscopic resection has been attempted, and in these cases, this does not predict submucosal invasion.

Knowing your expertise

As mentioned above, optimal and complete resection of large colon polyps is essential in preventing CRC. The United States Multi-Society Task Force (USMSTF) recommends an advanced endoscopist experienced in advanced polypectomy to manage polyps larger than > 20 mm in size.9 It is important to know your expertise and resources. This is because studies have shown that polyps which are endoscopically resectable are often sent for surgery.21According to one report, after endoscopic resection by expert endoscopists, only about 5-10% of patient subsequently require surgery.22 Therefore, resection should not be attempted unless the endoscopist is comfortable that resection will be complete. Incomplete polyp resections and biopsies cause submucosal fibrosis. Partial resections make subsequent endoscopic resection challenging, hence, the first attempt should always be aimed to complete resection.23 If an endoscopist feels a polyp will be challenging to resect or does not have available time for that, it is better to refer the patient to an endoscopist who is comfortable with advanced polypectomy techniques.

Tattoo placement

If an endoscopist deems that a polyp is unresectable, it is often advisable to place a tattoo so that polyp can be recognized easily by the endoscopist who the patient will be referred to. However, if cecal landmarks are in view, then tattoo placement is not necessary. 9 It is important to remember that tattoo placement can be problematic at times as well. Tattoo should never be placed in or under polyp itself. Carbon black spreads in the submucosa even if it is a few centimeters from the site of injection and extends beneath polyps causing submucosal fibrosis and rendering future endoscopic attempts complicated.23,24 Tattoos should be placed on an opposite wall from the polyp, or 5 cm distal to the polyp, with images depicting the lesion and its relationship to the tattoo.23,24

Endoscopic Management

Pedunculated Polyps

As mentioned above large polyps can be pedunculated or non-pedunculated. For pedunculated polyps that are greater than 10 mm in size, hot snare polypectomy is suggested.9 Attempts should be made to perform polypectomy towards the lower end of the stalk so assessment of stalk invasion can be made on histological analysis.9 For larger pedunculated polyps, consideration of epinephrine into the head or stalk of polyp can also be considered to reduce the size and make resection easier. Other strategies include using a detachable loop or placing clips at the polyp stalk before resection via hot snare. The USMSTF recommends that after resection, attempts should be made to retrieve large pedunculated polyps en-bloc so that accurate histological assessment can be made.9

Non-pedunculated polyps

The vast majority of non-pedunculated polyps can be removed using endoscopic mucosal resection (EMR). The various modalities implied in resection of large non-pedunculated polyps are described below. Algorithm for approaching management of large colon polyps is outlined in Figure 1.

Endoscopic mucosal resection

Endoscopic mucosal resection (EMR) involves submucosal injection of fluid to lift the lesion away from muscle and allow resection in single or multiple pieces. This technique has now evolved, and several sub-categories of this technique exists including hot EMR, cold EMR and underwater EMR. In expert hands, EMR is safe and effective. According to a systematic review of 50 studies, the reported rate of severe adverse events was 10% and the review also reported low rates of local recurrence (14%).25

Hot EMR

Hot snare EMR involves the use of electrocautery in polyp resection. The first step is submucosal injection. Submucosal injection can be achieved with using dye such as methylene blue with saline or there are commercially available submucosal injections available as well. Polyps which are < 20 mm in size can be removed en-bloc while polyps which are > 20 mm in size can be removed in piecemeal fashion. After submucosal injection is achieved and the lesion is adequately lifted, a snare is used to capture the tissue. After the lesion is captured in the snare, the snare is lifted up away from the mucosa and lesion is removed using electrocautery. When a polyp is removed piecemeal, ablation of the normal margins of the EMR defect using argon plasma coagulation or snare tip soft coagulation can burn microscopic residual tissue and reduce the risk of recurrence.9

Cold snare EMR

Over the past few years, another technique of EMR which has gained popularity is cold snare EMR.26,27 This technique allows for resection of large polyps without the use for electrocautery. The advantage of this technique is that it significantly reduces the adverse events associated with electrocautery such as bleeding and perforation. Initial data has been encouraging and has shown low rates of adverse events and comparable recurrence rates to hot snare EMR.28 While there is variation in technique, the basic principles involve using submucosal injection and using small diameter snare and removal of the polyp in multiple pieces.

Underwater EMR

Underwater EMR is another technique for resection of large colon polyps which allows full water immersion for polypectomy.29 It obviates the need for submucosal injection prior to polypectomy. Some experts report using argon plasma coagulation to mark the borders of the polyp.29,30

This is followed by immersing the segment of the colon polyp under water. All gas is aspirated from the colon and the mucosa and submucosa involute as folds into the colon.

Post resection considerations

Endoscopic clip placement

Bleeding is the most common adverse event after endoscopic mucosal resection. Risk factors for postpolypectomy bleeding include polyp size > 1 cm, presence of a thick stalk, use of anti-coagulation, right sided polyps and co-morbid conditions such as cardiovascular disease or renal dysfunction.31 In these cases, endoscopic clip placement after polypectomy can be considered. Endoscopic clip placement is usually not necessary after cold snare EMR since the risk of delayed bleeding is extremely low.30

Tattoo placement and surveillance

Tattoo placement should be considered when a polyp is resected in piecemeal fashion and is in a location which will be challenging to localize in the future.9 Tattoo placement is usually recommended 3-5 cm anatomically distal to the lesion.9

For large colon polyps that have been removed using piecemeal EMR, the USMSTF recommends the first surveillance colonoscopy at 6 months, and if there is no recurrence of polyp, then following examination should be performed at 1 and 3 year intervals respectively.9 Endoscopists should perform a careful exam of the resection site using high-definition white light endoscopy and narrow band imaging. Post-resection sites that demonstrate normal macroscopic and histological examination have high predictive values for long term eradication.32 If recurrence of polyp is seen on surveillance examination, attempts should be made at endoscopic resection with either repeat EMR, snare or avulsion method.9

Endoscopic Submucosal Dissection

Endoscopic submucosal dissection (ESD) allows for higher en-bloc resection rates as compared to EMR for lesions > 20 mm in size. Other instances when ESD should be considered include lesions where there is suspicion for submucosal invasion, local early carcinoma, and pseudodepressed laterally spreading tumor.33 ESD involves submucosal injection followed by use of an ESD knife to perform a mucosal incision. This is followed by trimming of the submucosal edges to facilitate access to the submucosal plane. Submucosal dissection is then performed resulting in en-bloc resection. While ESD has excellent rates of en-bloc resection, it has higher rates of adverse events compared to EMR, including perforation, hospitalization related to procedure and costs.34

Endoscopic Full-Thickness Resection

Endoscopic full-thickness resection (EFTR) is a relatively new approach which allows for removal of all layers of the colon wall.35,36 EFTR is indicated in lesions < 30 mm in size which do not lift or those which involve a diverticulum or lesions in the appendiceal orifice which are challenging to resect with traditional polypectomy methods.37 Commercially available full-thickness resection device is available (Ovesco Endoscopy AG, Tübingen, Germany) which is an over-the-scope system with a cap and a ready to use mounted clip and fitted snare.

Conclusion

Over the last decade, there has been a paradigm shift for management of large colon polyps from surgery to endoscopic resection. Optimal resection of large colon polyps is essential for preventing the incidence and mortality associated with colorectal cancer. Endoscopists should be comfortable at recognizing large colon polyps. Resection of large colon polyps should only be attempted by endoscopists who feel comfortable with advanced polypectomy techniques and if resources are not available, patients should be referred to an endoscopist who is familiar with large polyp resection.

References

  1. Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA: A Cancer Journal for Clinicians 2020;70:145-164.
  2. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
  3. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993;329:1977-81.
  4. Zauber AG, Winawer SJ, O’Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012;366:687- 96.
  5. De Ceglie A, Hassan C, Mangiavillano B, et al. Endoscopic mucosal resection and endoscopic submucosal dissection for colorectal lesions: A systematic review. Crit Rev Oncol Hematol 2016;104:138-55.
  6. Desai M, Bilal M, Hamade N, et al. Increasing adenoma detection rates in the right side of the colon comparing retroflexion with a second forward view: a systematic review. Gastrointest Endosc 2019;89:453-459.e3.
  7. Yang SY, Quan SY, Friedland S, et al. Predictive factors for adenoma detection rates: a video study of endoscopist practices. Endosc Int Open 2021;9:E216-e223.
  8. Wong WJ, Arafat Y, Wang S, et al. Colonoscopy withdrawal time and polyp/adenoma detection rate: a single-site retrospective study in regional Queensland. ANZ J Surg 2020;90:314-316.
  9. Kaltenbach T, Anderson JC, Burke CA, et al. Endoscopic Removal of Colorectal Lesions-Recommendations by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2020;158:1095-1129.
  10. Shaukat A, Kaltenbach T, Dominitz JA, et al. Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastrointest Endosc 2020;92:997-1015.e1.
  11. Shaukat A, Robertson D, Rex D. Endoscopic Recognition of Malignant Polyps. Gastroenterology 2021.
  12. van Doorn SC, Hazewinkel Y, East JE, et al. Polyp morphology: an interobserver evaluation for the Paris classification among international experts. Am J Gastroenterol 2015;110:180-7.
  13. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc 2003;58:S3-43.
  14. Hewett DG, Kaltenbach T, Sano Y, et al. Validation of a simple classification system for endoscopic diagnosis of small colorectal polyps using narrow-band imaging. Gastroenterology 2012;143:599-607.e1.
  15. Kudo S, Tamura S, Nakajima T, et al. Diagnosis of colorectal tumorous lesions by magnifying endoscopy. Gastrointest Endosc 1996;44:8-14.
  16. Aarons CB, Shanmugan S, Bleier JI. Management of malignant colon polyps: current status and controversies. World J Gastroenterol 2014;20:16178- 83.
  17. Matsuda T, Parra-Blanco A, Saito Y, et al. Assessment of likelihood of submucosal invasion in non-polypoid colorectal neoplasms. Gastrointest Endosc Clin N Am 2010;20:487-96.
  18. Uno Y, Munakata A. The non-lifting sign of invasive colon cancer. Gastrointest Endosc 1994;40:485-9.
  19. Ishiguro A, Uno Y, Ishiguro Y, et al. Correlation of lifting versus non-lifting and microscopic depth of invasion in early colorectal cancer. Gastrointest Endosc 1999;50:329-33.
  20. Kato H, Haga S, Endo S, et al. Lifting of lesions during endoscopic mucosal resection (EMR) of early colorectal cancer: implications for the assessment of resectability. Endoscopy 2001;33:568-73.
  21. Bronzwaer MES, Koens L, Bemelman WA, et al. Volume of surgery for benign colorectal polyps in the last 11 years. Gastrointest Endosc 2018;87:552-561. e1.
  22. Moss A, Williams SJ, Hourigan LF, et al. Long-term adenoma recurrence following wide-field endoscopic mucosal resection (WF-EMR) for advanced colonic mucosal neoplasia is infrequent: results and risk factors in 1000 cases from the Australian Colonic EMR (ACE) study. Gut 2015;64:57-65.
  23. Grimm IS, McGill SK. Look, but don’t touch: what not to do in managing large colorectal polyps. Gastrointest Endosc 2019;89:479-481.
  24. Kim HG, Thosani N, Banerjee S, et al. Effect of prior biopsy sampling, tattoo placement, and snare sampling on endoscopic resection of large nonpedunculated colorectal lesions. Gastrointest Endosc 2015;81:204- 13.
  25. Hassan C, Repici A, Sharma P, et al. Efficacy and safety of endoscopic resection of large colorectal polyps: a systematic review and meta-analysis. Gut 2016;65:806-20.
  26. Choksi N, Elmunzer BJ, Stidham RW, et al. Cold snare piecemeal resection of colonic and duodenal polyps ≥1 cm. Endosc Int Open 2015;3:E508-13.
  27. Piraka C, Saeed A, Waljee AK, et al. Cold snare polypectomy for non-pedunculated colon polyps greater than 1 cm. Endosc Int Open 2017;5:E184-e189.
  28. Tutticci NJ, Hewett DG. Cold EMR of large sessile serrated polyps at colonoscopy (with video). Gastrointest Endosc 2018;87:837-842.
  29. Binmoeller KF, Weilert F, Shah J, et al. “Underwater” EMR without submucosal injection for large sessile colorectal polyps (with video). Gastrointest Endosc 2012;75:1086-91.
  30. Binmoeller KF, Hamerski CM, Shah JN, et al. Attempted underwater en bloc resection for large (2-4cm) colorectal laterally spreading tumors (with video). Gastrointest Endosc 2015;81:713-8.
  31. Buddingh KT, Herngreen T, Haringsma J, et al. Location in the right hemi-colon is an independent risk factor for delayed post-polypectomy hemorrhage: a multi-center case-control study. Am J Gastroenterol 2011;106:1119-24.
  32. Khashab M, Eid E, Rusche M, et al. Incidence and predictors of “late” recurrences after endoscopic piecemeal resection of large sessile adenomas. Gastrointest Endosc 2009;70:344-9.
  33. Tanaka S, Saitoh Y, Matsuda T, et al. Evidencebased clinical practice guidelines for management of colorectal polyps. J Gastroenterol 2015;50:252-60.
  34. Fujiya M, Tanaka K, Dokoshi T, et al. Efficacy and adverse events of EMR and endoscopic submucosal dissection for the treatment of colon neoplasms: a meta-analysis of studies comparing EMR and endoscopic submucosal dissection. Gastrointest Endosc 2015;81:583-95.
  35. Schmidt A, Bauerfeind P, Gubler C, et al. Endoscopic full-thickness resection in the colorectum with a novel over-the-scope device: first experience. Endoscopy 2015;47:719-25.
  36. Vitali F, Naegel A, Siebler J, et al. Endoscopic fullthickness resection with an over-the-scope clip device (FTRD) in the colorectum: results from a university tertiary referral center. Endosc Int Open 2018;6:E98- e103.
  37. Schmidt A, Beyna T, Schumacher B, et al. Colonoscopic full-thickness resection using an over-the-scope device: a prospective multicentre study in various indications. Gut 2018;67:1280-1289.

Download Tables, Images & References

MEDICAL BULLETIN BOARD

Cellmax Life and Sebela Pharmaceuticals Enter Strategic Development and Commercialization Partnership for Firstsight™ Blood Test for Detection of Colorectal Cancer and Pre-cancer

Read Article

CellMax Life closes Series C financing to accelerate development and regulatory approvals of FirstSight

SUNNYVALE, CA and ROSWELL, GA (March, 2021) – CellMax Life, a molecular diagnostics company with proprietary technology for pre-cancer and cancer detection blood tests, and Sebela Pharmaceuticals, a market leader in gastroenterology, announce the closing of a strategic development and commercial collaboration agreement, as well as CellMax’s Series C financing. Participation in the financing also includes a strategic investment from new investor, Aflac Ventures, the corporate venture arm of Aflac Incorporated (NYSE: AFL), and existing investor, ArtimanVentures.

“Strategic financing from market leaders, Sebela and Aflac Ventures, is a testament to CellMax’s technology and vision,” said Atul Sharan, chief executive officer, CellMax Life. “Sebela has a leading market position in the gastroenterology field in the United States. The financing will bring to life our vision of detecting colon cancer before it occurs through a globally marketed blood test that can detect pre-cancerous polyps.”

The Series C financing will be used to accelerate the clinical development of CellMax’s multimodal liquid biopsy test, FirstSight™, for the detection of colorectal cancer and pre-cancerous polyps, also known as advanced adenomas. CellMax recently initiated a multicenter U.S. study to further optimize its proprietary algorithm and cell capture techniques. CellMax and Sebela will collaborate on completing the development of FirstSight and, following approval from the U.S. Food and Drug Administration, Sebela will commercialize the test in the United States.

“For the last several years, we have closely followed the industry’s development of colorectal cancer liquid biopsies,” said Alan Cooke, chief executive officer, Sebela Pharmaceuticals. “Sebela and our subsidiary, Braintree, have worked with gastroenterologists for over 35 years, and we expect FirstSight to play a central role in the future of colorectal cancer screening. FirstSight may not only enable the U.S. to exceed its 80% screening rate target, as set by the National Colorectal Cancer Roundtable, but can also help detect pre-cancerous adenomas early, referring patients to colonoscopy for preemptive removal.”

This partnership complements Sebela’s portfolio of market-leading gastroenterology and colonoscopy preparation products, which are utilized to facilitate colonoscopies, the “gold standard” for the prevention and detection of colorectal cancer. Colonoscopies remain the only means of removing detected pre-cancerous lesions to prevent colorectal cancer.

At the 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium, Dr. Shai Friedland, professor of medicine at Stanford University Medical Center and chief of gastroenterology at the VA Palo Alto Health Care System, presented results from a prospective study performed on 458 subjects utilizing FirstSight, a multimodal assay comprised of circulating dysplastic epithelial cells and circulating tumor DNA mutation markers, in combination with a proprietary algorithm.

“A test that detects only colorectal cancer, and not adenomas, will result in missed opportunities to prevent cancer and subject patients to invasive cancer treatments,” said Dr. Friedland. “Today, there is not a single non-invasive screening test that can accurately detect pre-cancerous polyps even nearly as effective as a colonoscopy. Our study data with the FirstSight blood test continues to show consistent ability to detect advanced adenomas with high sensitivity, enabling removal before they progress to carcinomas.”

In clinical studies performed in the U.S. and Taiwan, FirstSight has demonstrated strong performance in detecting both advanced adenomas and colorectal cancer. FirstSight has also shown the ability to detect recurrent neoplasia following polypectomy. i-v [i], [ii], [iii], [iv], [v]

Colorectal cancer represents the second deadliest cancer in the U.S., despite being one of the most preventable.[vi] Additionally, screening adherence rates have fallen short of the 80% target, as only 68.8% of adults aged 50 to 75 years, and only 63.3% of adults aged 50 to 64 years, were up to date with colorectal cancer screening as of 2018.[vii]

About CellMax Life

CellMax Life is a diagnostics company focused on cancer screening with proprietary technology for detecting precancerous and cancer cells and genomic aberrations in a single blood sample. CellMax Life is headquartered in Sunnyvale, California, and has a CLIA certified and CAP accredited laboratory at this location.

For more information, visit: cellmaxlife.com

About Sebela Pharmaceuticals®

Sebela Pharmaceuticals is a growth oriented pharmaceutical company focused in gastroenterology, colorectal cancer detection and prevention. Braintree, a part of Sebela Pharmaceuticals, is a pioneer in colonoscopy screening with a broad marketed portfolio of innovative prescription colonoscopy preparations and gastroenterology products. Braintree has multiple clinical development programs including, in collaboration with Cellmax Life, a multimodal liquid biopsy test, FirstSight™, for the detection of colorectal cancer and pre-cancerous polyps. Sebela’s core therapeutic areas also include women’s health and dermatology. In women’s health, Sebela has two next generation intra-uterine devices (IUDs) for contraception in late-stage clinical development. Sebela Pharmaceuticals has offices in Roswell, GA; Braintree, MA; and Dublin, Ireland; has annual net sales of $200-250 million; and has grown to over 300 employees through strategic acquisitions and organic growth. Please visit sebelapharma.com for more information.

About Aflac Incorporated

Aflac Incorporated (NYSE: AFL) is a Fortune 500 company helping provide protection to more than 50 million people through its subsidiaries in Japan and the U.S., where it is a leading supplemental insurer by paying cash fast when policyholders get sick or injured. For more than six decades, insurance policies of Aflac Incorporated’s subsidiaries have given policyholders the opportunity to focus on recovery, not financial stress. Aflac Life Insurance Japan is the leading provider of medical and cancer insurance in Japan where it insures 1 in 4 households. For 15 consecutive years, Aflac Incorporated has been recognized by Ethisphere as one of the World’s Most Ethical Companies. In 2021, Fortune included Aflac Incorporated on its list of World’s Most Admired Companies for the 20th time, and Bloomberg added Aflac Incorporated to its Gender-Equality Index, which tracks the financial performance of public companies committed to supporting gender equality through policy development, representation and transparency, for the second consecutive year.

To find out how to get help with expenses health insurance doesn’t cover, get to know us at: aflac.com

Forward Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sebela Pharmaceuticals under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These statements may be identified by the use of forward-looking words such as “anticipate,” “planned,” “believe,” “forecast,” “estimated,” “expected,” and “intend,” among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the development, launch, introduction and commercial potential of FirstSight™; growth and opportunity, including peak sales and the potential demand for FirstSight™, as well as its potential impact on applicable markets; market size; substantial competition; our ability to continue as a growing concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or thirdparty payer reimbursement; dependence upon third parties; our financial performance and results, including the risk that we are unable to manage our operating expenses or cash use for operations, or are unable to commercialize our products, within the guided ranges or otherwise as expected; and risks related to failure to obtain FDA and/or CMS clearances or approvals and noncompliance with FDA regulations. As with any diagnostic under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forwardlooking statements included herein are made as of the date hereof, and Sebela Pharmaceuticals does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances except as required by law.

Download Tables, Images & References

MEDICAL BULLETIN BOARD

Lilly’s Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-week Phase 3 Induction Study

Read Article

  • Patients treated with mirikizumab met the primary endpoint of clinical remission and all key secondary endpoints compared to placebo
  • LUCENT-1 is the first and only Phase 3 study of an anti-IL23p19 monoclonal antibody to demonstrate reduced bowel urgency in moderate to severe ulcerative colitis
  • Safety results in this study were consistent with that of the previous mirikizumab study in ulcerative colitis and studies with the anti-IL-23p19 antibody class

INDIANAPOLIS, March, 2021 – Eli Lilly and Company (NYSE: LLY) announced that mirikizumab met the primary and all key secondary endpoints in LUCENT-1, a 12-week Phase 3 induction study evaluating the efficacy and safety of mirikizumab for the treatment of patients with moderate to severe ulcerative colitis (UC). LUCENT-2, a multicenter, randomized, doubleblind, placebo-controlled maintenance study of mirikizumab in patients who have completed the 12-week LUCENT-1 induction study is ongoing.

UC is a chronic inflammatory disease of the large intestine, also referred to as the colon, that affects the lining of the colon and may cause small sores, or ulcers, to form. [i] This inflammation can cause abdominal pain, frequent and urgent trips to the bathroom, bloody stools and incontinence.1 UC can cause significant and debilitating disruptions in daily life. Millions of people live with UC globally.2

“There is a continued need for additional treatments that can provide people living with ulcerative colitis relief from their most challenging symptoms,” said William J. Sandborn, MD, Professor of Medicine, and Chief, Division of Gastroenterology, University of California San Diego. “Results of this study provide further clinical evidence of the potential for mirikizumab to become the first anti-IL-23p19 biologic for the treatment of ulcerative colitis.”

In LUCENT-1, mirikizumab met the primary endpoint of clinical remission at Week 12 compared to placebo (p<0.0001). Clinical remission is met when inflammation of the colon is controlled or resolved, leading to normalization or nearnormalization of symptoms such as stool frequency and bleeding.

Mirikizumab also achieved all key secondary endpoints compared to placebo at Week 12 in patients with UC with highly statistically significant p-values, including reduced bowel urgency, clinical response, endoscopic remission, symptomatic remission and improvement in endoscopic histologic inflammation. In addition, mirikizumab demonstrated rapid improvement in patient symptoms as early as four weeks after initiating treatment. Mirikizumab also reduced symptoms among patients who had previously not responded to or stopped responding to biologic and/or Janus kinase (JAK) inhibitor therapies.

In the 12-week placebo-controlled induction study of LUCENT-1, the incidence of treatmentemergent adverse events (AEs) and serious AEs among patients treated with mirikizumab was consistent with that of the previous Phase 2 mirikizumab study in UC and studies with the antiIL-23p19 antibody class. The most common AEs included nasopharyngitis, anemia and headache for both placebo and mirikizumab-treated patients.

“People living with UC often struggle to effectively manage recurring flare ups of the disease,” said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly. “With these positive results, we look forward to the continuation of the maintenance study through 52 weeks in hopes of providing a new option to people living with UC.”

“Ulcerative colitis can be debilitating and unpredictable for the hundreds of thousands of people living with this chronic disease,” said Dr. Caren Heller, Chief Scientific Officer for the Crohn’s & Colitis Foundation. “We’re encouraged by these promising results for a potential new treatment that may help provide symptom relief and remission.”

About Mirikizumab

Mirikizumab is a humanized IgG4 monoclonal antibody that binds to the p19 subunit of interleukin23. Mirikizumab is being studied for the treatment of immune diseases, including psoriasis, ulcerative colitis and Crohn’s disease.

About the LUCENT Clinical Trial Program

The LUCENT Phase 3 clinical development program for mirikizumab includes LUCENT-1, LUCENT-2 and LUCENT-3. LUCENT-1 (NCT03518086) is a multicenter, randomized, double-blind, placebocontrolled, Phase 3 induction study of mirikizumab in patients with moderate to severe UC who had failed conventional and/or biologic treatments. LUCENT-2 (NCT03524092) is a multicenter, randomized, double-blind, placebo-controlled maintenance study of mirikizumab in patients who have completed the 12-week LUCENT-1 induction study. LUCENT-3 (NCT03519945) is an open label extension study for eligible patients who have participated in mirikizumab UC trials.

The program began in 2018, with full results from the induction and maintenance studies anticipated in early 2022.

About Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory bowel disease that affects the colon.1 UC occurs when the immune system sends white blood cells into the lining of the intestines, where they produce chronic inflammation and ulcerations.3 There is an unmet need for additional treatment options for UC that provide meaningful symptom relief, including bowel urgency, and deliver sustained clinical remission.

About Eli Lilly and Company

Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring lifechanging medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

To learn more about Lilly, please visit us at: lilly.com and lilly.com/newsroom

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about mirikizumab as a potential treatment for patients with ulcerative colitis and other diseases and reflects Lilly’s current beliefs and expectations. As with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there can be no guarantee that future study results will be consistent with study results to date, that mirikizumab will prove to be a safe and effective treatment or that mirikizumab will receive regulatory approvals or be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly’s most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

  1. Overview of Ulcerative Colitis. Crohn’s and Colitis Foundation Website.https://www.crohnscolitisfoundation.org/what-is-ulcerativecolitis/overview. Accessed February 2021.
  2. Adelphi Data 2017.
  3. What is Ulcerative Colitis? Crohn’s and Colitis Foundation Website. http://www.crohnscolitisfoundation.org/what-are-crohns-and-colitis/ what-is-ulcerative-colitis/. Accessed February 2021

Download Tables, Images & References

FROM THE PEDIATRIC LITERATURE

Teduglutide and Short Bowel Syndrome in Children

Read Article

Intestinal failure due to short bowel syndrome (SBS) is disabling as well as life-threatening in children. Teduglutide is a glucagon-like peptide-2 which promotes intestinal growth and bowel adaption. There is minimal data in children regarding the efficacy of this new medication, and the authors of this prospective, multi-center study followed 17 children with SBS who were treated with teduglutide at 0.05mg/kg/day via the subcutaneous route. All included patients had less than 100 cm of remaining bowel (except for 2 patients), were on parenteral nutrition (PN), and had no surgical intervention or changes in PN for 3 months prior to teduglutide use. At each clinic visit (baseline, 3 months, 6 months, and 12 months after therapy), information on PN volume, nutritional support, recorded stool losses, plasma citrulline levels, and the presence of adverse events were recorded. Any patient with a reduction in PN by 20% was defined as a “responder”. All patients were older than one year of age, and all patients developed intestinal failure after birth. The most common cause of intestinal failure was necrotizing enterocolitis. These patients were receiving an average 55 mL/kg/day of fluid volume daily (range 8-210 mL/kg/day) and were receiving 33 kcal/k/ day of nutritional support (range 0-65 kcal/kg/ day). Their mean initial citrulline level was 20 micromoles/L (range 7.8-51 micromoles/L).

A total of 15 of the 17 patients were able to complete one year of teduglutide. By the 3-month follow up, 3 patients had achieved full enteral autonomy. This trend continued with an additional 4 patients and then 3 patients reaching full enteral autonomy at 6 months and 12 months, respectively. Most patients were able to reduce their fluid volume and nutritional support, and in total, 14 of the 15 patients who finished the therapeutic study were responders to teduglutide. A 20% or greater reduction in PN support was noted in 47%, 87%, and 93% of patients at 3, 6, and 12 months respectively, while 17%, 44%, and 60% of patients were able to wean off of PN at 3, 6, and 12 months respectively. Stool output improved and citrulline levels increased in all patients throughout the study. The most common adverse events consisted of abdominal pain occurring in 30% of patients, followed by injection-site reactions, nausea, headaches, abdominal distention, and the presence of upper respiratory tract infections. Most of these side effects were mild or moderate.

This small study demonstrates promising results regarding the efficacy of teduglutide in the treatment of pediatric intestinal failure. More research is needed for children with an even greater loss of bowel as well as determination of cost savings associated with teduglutide use.

Boluda E, Ferreiro S, Moral O, Romero R, Terradillows I, Ramos R, Diaz M, Miquel B, Pinera I, Sanchez A, Sacristan R, Barea M, Villares J. Experience with teduglutide in pediatric short bowel syndrome: first real-life data. Journal of Pediatric Gastroenterology and Nutrition 2020; 71: 734-739.

Download Tables, Images & References

FROM THE PEDIATRIC LITERATURE

How Common are Pediatric Feeding Disorders?

Read Article

Feeding disorders in children commonly are seen in both the primary care and pediatric gastroenterology setting. There is no good epidemiologic data about the prevalence of pediatric feeding disorders in children in the United States. Thus, the authors of this study used de-identified data from the Truven Health Analytics MarketScan Commercial Claims and Encounters Database (Ann Arbor, Michigan) for patients with private insurance as well as Arizona and Wisconsin Medicaid data for patients with Medicaid covering the time period from 2009 to 2014. Children between 2 months and 18 years were included in the study, and the authors used 25 International Classification of Diseases (ICD)-9 and ICD-10 codes to identify potential study subjects as there is no specific “feeding disorder” diagnosis code for children. Children who had been diagnosed with one of these codes and not with an eating disorder were included. The authors evaluated all such patients for comorbid conditions, the presence of malnutrition/ failure to thrive, and the presence of a gastrostomy tube. Children were identified as having a complex chronic condition (CCC) based on known ICD codes if they had a medical condition expected to last at least 12 months and had at least one organ system involvement which could require pediatric subspecialty care and potential hospitalization.

The presence of feeding disorders increased in all databases during the time period with significantly more children covered by Medicaid having feeding disorders (Arizona, 16.97 per 1000 child-years; 95% CI, 16.84-17.10 and Wisconsin, 21.43 per 1000 child-years; 95% CI, 21.27-21.60) compared to children covered with private insurance (9.38 per 1000 child-years; 95% CI, 9.35-9.40). A lower prevalence of feeding disorders was present in older patients (defined as 12-18 years old), and more males had feeding disorders compared to females throughout the study. Specific patients with CCC (including children with respiratory, gastrointestinal, miscellaneous technology dependency, prematurity/neonatal risk, and organ transplantation) had higher rates of feeding disorders, and the prevalence of feeding disorders in children with a CCC increased throughout the study despite no increase in the number of children with a feeding disorder and without a CCC. Although the prevalence of malnutrition in children with a feeding disorder decreased in all databases throughout the study, children with an associated CCC had a higher prevalence of a malnutrition. The prevalence of gastrostomy tubes decreased in this population throughout the study period, and most children who had both a feeding disorder and a gastrostomy tube also had an associated CCC. This study demonstrates that pediatric feeding disorders are increasing in children in the United States, and this disorder is commonly associated with the presence of a CCC. Thus, we need early intervention as well as improved long-term treatment options for this population as well as better accuracy in ICD coding in order to track and to care for these children over time.

Kovacic K, Rein L, Szabo A, Kommareddy S, Bhagavatula P, Goday P. Pediatric feeding disorder: a nationwide prevalence study. Journal of Pediatrics 2021; 228: 126-131.

Download Tables, Images & References

FROM THE LITERATURE

Gastric Cancer Incidence Among Races and Ethnicities in Patients Age 50 Years and Older

Read Article

To evaluate the racial and ethnic differences in the incidence of gastric adenocarcinoma worldwide and in the United States, based on a decision analysis, screening for noncardia gastric adenocarcinoma might be cost-effective for non-White individuals 50 years or older. A lack of precise contemporary information on gastric adenocarcinoma incidence in specific anatomic sites for this age group has impeded prevention and early detection programs in the U.S.

To estimate the differences in gastric adenocarcinoma incidence in specific anatomic sites among races and ethnicities in individuals 50 years or older, the California Cancer Registry data from 2011 through 2015 was evaluated to estimate incidences of gastric adenoma in specific anatomic sites for non-Hispanic White (NHW), non-Hispanic black, Hispanic and the seventh largest Asian-American populations. Calculation was carried out as to the differential incidence between non-White groups and NHW, using incidence rate ratios and 95% confidence intervals (CIs).

Compared with NHW subjects, all non-White groups had significantly higher incidences of noncardiac gastric adenocarcinoma. The incidence was highest among Korean-American men 50 years and older (70 cases per 100,000). Compared with NHW subjects 50 years and older, the risk of noncardiac gastric adenocarcinoma was 1.8-fold to 7.3-fold, higher in most non-White groups and 12- fold to 14.5-fold higher among Korean-American men and women 50 years and older, respectively.

Compared with NHW men 50 years and older, all non-White men, except Japanese and KoreanAmerican men had a significantly lower risk of cardia gastric adenocarcinoma.

There was identification of several-fold differences in evidence of gastric adenocarcinoma in specific anatomic sites among racial and ethnic groups, with significant age and sex differences. These findings should be used to develop targeted risk reduction programs for gastric adenocarcinoma.

Shah, S., McKinley, M., Gupta, S., et al. “Population-Based Analysis of Differences in Gastric Cancer Incidence Among Races and Ethnicities in Individuals Aged 50 Years and Older.” Gastroenterology 2020; Vol. 159, pp. 1705-1714.

Download Tables, Images & References

FROM THE LITERATURE

Effects of Statin Drugs in Nonalcoholic Fatty Liver Disease

Read Article

To investigate the role of statins on the development of de novo NAFLD and progression of significant liver fibrosis, a study was carried out, including 11,593,409 subjects from the NHI database of the Republic of Korea. This was entered in 2010 and followed until 2016. NAFLD was diagnosed by calculating fatty liver index (FLI) and significant liver fibrosis was evaluated using the BARD score. Controls were randomly selected at a ratio of 1:5 from individuals who were at risk of becoming case subjects at the time of selection.

Among 5,339,901 subjects that had FLI less than 30 and included in the non-NAFLD cohort, a total of 164,856 subjects eventually had NAFLD develop. The use of statin was associated with a reduced risk of NAFLD development (adjusted odds ratio; AOR 0.66), and was independent of associated diabetes mellitus {DM}; AOR 0.44, without DM, AOR 7.1). From 712,262 subjects with FLI greater than 60 and selected in the NAFLD cohort, 111,257 subjects showed a BARD score greater than 2 and were defined as liver fibrosis cases.

The use of statins reduces the risk of significant liver fibrosis (AOR 0.43, independent of diabetes, with DM; AOR 0.31, without DM, AOR 0.52).

In this large population-based study, statin use decreased the risk of NAFLD occurrence and the risk of liver fibrosis once NAFLD developed.

Lee, J., Lee, H., Lee, K., Lee, H., Park, J. “Effects of Statin Use on the Development and Progression of Nonalcoholic Fatty Liver Disease: A Nationwide, Nested Case-Controlled Study.” American Journal of Gastroenterology, Vol. 116, January 2021, pp. 116-124.

Download Tables, Images & References

FROM THE LITERATURE

Mortality in Patients with Cirrhosis and COVID-19

Read Article

To evaluate the impact of COVID-19 on the clinical outcome of patients with cirrhosis in a multi-center, retrospective study, patients with cirrhosis and the confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection were enrolled between 3/1/2020 and 3/31/2020. Clinical and biochemical data and diagnosis of COVID-19 at the last outpatient visit were obtained through review of medical records.

A total of 50 patients with cirrhosis and with confirmed SARS-CoV-2 infection were enrolled (age 67, 70% men, 38% virus-related, 52% previously compensated cirrhosis), 64% of patients presented fever, 42% shortness of breath, polypnea, 22% encephalopathy, 96% either hospitalization or a prolonged stay if already in hospital. Respiratory support was necessary in 71%, 52% received antivirals, 80% heparin.

Serum albumin significantly decreased while bilirubin, creatinine and prothrombin time significantly increased at COVID-19 diagnosis, compared to last available data.

The proportion of patients with a MELD score greater than 15 increased from 13% to 26%, acuteon-chronic liver failure and de novo acute liver injury occurred in 14 (28%), and 10 patients, respectively. A total of 17 patients died after a median of 10 days from COVID-19 diagnosis with a 30-day mortality rate of 34%. The severity of lung and liver disease has independently predicted mortality. In patients with cirrhosis, mortality was significantly higher in those with COVID-19 than in those hospitalized for bacterial infections.

It was concluded that COVID-19 is associated with liver function deterioration and elevated mortality in patients with cirrhosis.

Lavarone, M., D’Ambrosio, R., Soria, A., et al. “High Rates of 30-Day Mortality in Patients with Cirrhosis and COVID-19.” Journal of Hepatology 2020; Vol. 73, pp. 1063-1071.

Download Tables, Images & References

FROM THE LITERATURE

Risk Factors for Cirrhosis in Long-Term Alcohol Utilization

Read Article

In order to assist in the discovery of mechanisms and prediction of risk, apart from lifetime alcohol exposure to produce alcohol-related cirrhosis, patients were evaluated, noting that sustained alcoholic intake is necessary, but not sufficient to produce alcohol related cirrhosis

A multi-center, case-controlled study (GenomALC) comparing 1293 cases (with alcoholrelated cirrhosis, 75.6% male), and 754 controls (with equivalent alcohol exposure, but no evidence of liver disease, 73.6% male) was carried out. Information confirming or excluding cirrhosis and on alcoholic intake and other potential risk factors was obtained from clinical recurs and by interview. Case-control differences and risk factors discovered in the GenomALC participants was validated using similar data from 407 cases and 6573 controls from UK Biobank.

The GenomALC case and control groups reported similar lifetime alcoholic intake (1374 vs 1412 kg). Cases had a higher prevalence of diabetes (20.5% vs 6.5%), and higher pre-morbid body mass index (26.37), than controls (24.4). Controls are significantly more likely to have been wine drinkers, coffee drinkers, smokers, and cannabis users than cases. Cases reported a higher proportion of parents who died of liver disease than controls (OR 2.25). Data from UK Biobank confirmed these findings with diabetes, BMI, proportion of alcohol as wine, and coffee consumption.

If these relationships can be identified as causal, measures such as weight loss, intensive treatment of diabetes or prediabetic states, and coffee consumption should reduce the risk of alcohol-related cirrhosis.

Whitfield, J., Masson, S., Liangpunsakul, S., et al. for the GenomALC Consortium. “Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in Two Large Cohorts of High-Risk Drinkers.” American Journal of Gastroenterology; January 2021, Vol. 16, pp. 106-115.

Download Tables, Images & References

FROM THE LITERATURE

Risk Factors for Delta Hepatitis in a North American Cohort with Indications for Screening

Read Article

A study of American patients with hepatitis B (HBV) referred to the NIH was performed to identify risk factors associated with HDV infection. Active HDV was “confirmed” by serum HDV-DNA or histologic HDV antigen staining.

A total of 652 patients were studied, of which 91 were HDV “confirmed.” Independent risk factors for HDV included: intravenous drug users, HDV-DNA less than 2000 i.u./mL, ALT greater than 40 units per liter and HDV endemic country of origin.

The discussion indicated that North American patients with HBV and significant risk factors should be screened for HDV.

Da, B., Rahmen, F., Lai, W., et al. “Risk Factors for Delta Hepatitis in a North American Cohort: Who Should Be Screened?” American Journal of Gastroenterology; Vol. 116, January 2021, pp. 206-209.

Download Tables, Images & References

jojobethacklinkmarsbahisJojobet GirişcasibomJojobet GirişCasibomCasibomvaycasinoholiganbetcasibommarsbahis girişJojobettaraftarium24madridbet güncel girişmadridbet girişmadridbetGrandpashabet